Skip to main content

Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.

Publication ,  Journal Article
Harrison, MR; Wong, TZ; Armstrong, AJ; George, DJ
Published in: Cancer Manag Res
2013

BACKGROUND: Radium-223 chloride ((223)Ra; Alpharadin) is an alpha-emitting radioisotope that targets areas of osteoblastic metastasis and is excreted by the small intestine. When compared with beta-emitters (eg, strontium-89, samarium-153), (223)Ra delivers a high quantity of energy per track length with short tissue penetration. OBJECTIVE: This review describes the mechanism, radiobiology, and preclinical development of (223)Ra and discusses the clinical data currently available regarding its safety and efficacy profile. METHODS: Data from clinical trials including abstracts were collected and reviewed using the PubMed Database, as well as the American Society of Clinical Oncology abstract database. CONCLUSION: Current bone-targeted therapies fall into two main categories: antiresorptive agents (eg, zoledronic acid, denosumab), which have been shown to delay skeletal-related events, and radiopharmaceuticals (eg, samarium-153), which may have a role in pain palliation. Historically, neither antiresorptive agents nor radiopharmaceuticals have shown definitive evidence of improved overall survival or other antitumor effects in metastatic castrate-resistant prostate cancer (mCRPC). Radiopharmaceuticals are limited by myelosuppresion, thrombocytopenia, and renal excretion. In a recently reported randomized Phase III trial in men with symptomatic bone-metastatic CRPC who had received or were ineligible for docetaxel chemotherapy, (223)Ra treatment resulted in improved overall survival and delayed skeletal-related events. Toxicity consisted of minor gastrointestinal side effects and mild neutropenia and thrombocytopenia that were rarely severe. Pending regulatory approval, (223)Ra may represent a unique and distinct option for an important subgroup of patients with mCRPC; future trials should address its use in combination or in sequence with existing and novel agents.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Manag Res

DOI

ISSN

1179-1322

Publication Date

2013

Volume

5

Start / End Page

1 / 14

Location

New Zealand

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Harrison, M. R., Wong, T. Z., Armstrong, A. J., & George, D. J. (2013). Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res, 5, 1–14. https://doi.org/10.2147/CMAR.S25537
Harrison, Michael R., Terence Z. Wong, Andrew J. Armstrong, and Daniel J. George. “Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.Cancer Manag Res 5 (2013): 1–14. https://doi.org/10.2147/CMAR.S25537.
Harrison, Michael R., et al. “Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.Cancer Manag Res, vol. 5, 2013, pp. 1–14. Pubmed, doi:10.2147/CMAR.S25537.

Published In

Cancer Manag Res

DOI

ISSN

1179-1322

Publication Date

2013

Volume

5

Start / End Page

1 / 14

Location

New Zealand

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis